Newly Created Leadership Role Reinforces PHC
Group Commitment to Diabetes Innovation
PHC Holdings Corporation (TSE: 6523) (hereafter PHCHD), the
parent company of Ascensia Diabetes Care, a global diabetes care
company, along with Senseonics Holdings, Inc. (NYSE American:
SENS), a medical technology company focused on the development and
manufacturing of long-term, implantable continuous glucose
monitoring (CGM) systems for people with diabetes, today announced
that diabetes industry veteran Brian Hansen has been appointed to
the newly created role of President of CGM at Ascensia Diabetes
Care, effective February 6, 2024. Ascensia is the exclusive global
distributor of the Eversense® E3 CGM system developed and
manufactured by Senseonics.
Mr. Hansen will be responsible for the global commercialization
and growth of the innovative Eversense CGM, currently available in
the U.S. and select European markets. The Eversense CGM is the
industry's first and only fully implantable CGM system and allows
continuous measurement of glucose levels for up to six months,
compared to just one or two weeks with most CGM systems. Alongside
improved longevity, this next-generation system also offers people
with diabetes unique and competitive features such as a removable
smart transmitter1, discreet on-body vibe alerts, exceptional
accuracy2, and an intuitive smartphone app.
Mr. Hansen previously served as Chief Commercial Officer for
Tandem Diabetes Care, where he helped transform the company into a
worldwide market leader, increasing patient utilization of Tandem
products in the highly competitive insulin pump market. He has
built a reputation for launching innovative products and overcoming
commercial challenges with complex medical and regulatory
landscapes. Previously, Mr. Hansen also held leadership positions
at Adaptive Biotechnologies, Genoptix, Gen Probe, and Thermo Fisher
Scientific. He holds a number of advisory board positions,
including for Spotlight-AQ, Luminoah and the University of
Missouri.
Koichiro Sato, COO of PHCHD, known collectively with its
subsidiaries as PHC Group, said, “Eversense is a game-changer for
people with diabetes and is an essential part of both Ascensia’s
commitment to providing high-quality and life-enhancing products
and PHC Group’s global business strategy. Brian is ideally suited
to lead our CGM business and enable us to realize the full
potential of Eversense in the CGM market.”
Tim Goodnow, CEO of Senseonics, said, “We are thrilled that
Ascensia has built out a dedicated CGM arm to drive patient and
provider adoption of Eversense. This is a testament to our
partnership and the ongoing collaboration between PHCHD, Ascensia
and Senseonics. We look forward to working with Brian and
leveraging his extensive industry experience to catalyze the next
phase of growth for Eversense. Together our top priority will be
evaluating and optimizing the strategy to deliver the benefits of
Eversense to the most patients globally as we work to advance the
revolutionary 365-day system to the market.”
Robert Schumm, President of Ascensia, added, “Our
commercialization of Eversense is building momentum as we work to
drive more and more awareness of the unique benefits of Eversense.
We look forward to welcoming Brian to our motivated and passionate
team, and expect his wealth of experience delivering breakthrough
diabetes devices will help us to unleash Eversense’s full
commercial potential.”
Eversense is a key driver of Ascensia’s mission to empower
people living with diabetes through solutions that simplify and
improve their lives. Ascensia is also the maker of the
world-renowned CONTOUR® portfolio of blood glucose monitoring (BGM)
systems, available in more than 100 countries. Mr. Schumm will
continue in his current role while shifting focus to the company’s
BGM business.
Senseonics plans to provide its financial outlook for the first
half of 2024 in its upcoming fourth quarter and full year 2023
earnings conference call at the end of February 2024. The full year
2024 growth outlook will be provided in the second quarter 2024
following an assessment of the current commercial plan by the new
President of CGM at Ascensia Diabetes Care.
About PHC Holdings Corporation
PHC Holdings Corporation (TSE 6523) is a global healthcare
company with a mission of contributing to the health of society
through healthcare solutions that have a positive impact and
improve the lives of people. Its subsidiaries include PHC
Corporation, Ascensia Diabetes Care Holdings AG, Epredia, LSI
Medience Corporation, Mediford Corporation, and Wemex. Together,
these companies develop, manufacture, sell and service solutions
across diabetes management, healthcare solutions, life sciences and
diagnostics. PHC Group’s consolidated net sales in FY2022 were JPY
356.4 billion with global distribution of products and services in
more than 125 countries. www.phchd.com
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology
company focused on the development and manufacturing of glucose
monitoring products designed to transform lives in the global
diabetes community with differentiated, long-term implantable
glucose management technology. Senseonics’ CGM system Eversense® E3
includes a small sensor inserted completely under the skin that
communicates with a smart transmitter worn over the sensor. The
glucose data are automatically sent every 5 minutes to a mobile app
on the user’s smartphone.
About Eversense
The Eversense® E3 CGM System is indicated for continually
measuring glucose levels for up to 180 days in persons with
diabetes age 18 and older. The system is indicated for use to
replace fingerstick blood glucose (BG) measurements for diabetes
treatment decisions. Fingerstick BG measurements are still required
for calibration primarily one time a day after day 21, and when
symptoms do not match CGM information or when taking medications of
the tetracycline class. The sensor insertion and removal procedures
are performed by a health care provider. The Eversense E3 CGM
System is a prescription device; patients should talk to their
health care provider to learn more. For important safety
information, see
https://www.ascensiadiabetes.com/eversense/safety-info/.
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global company focused entirely on
helping people with diabetes. Its mission is to empower those
living with diabetes through innovative solutions that simplify and
improve their lives. It is home to the world-renowned CONTOUR®
portfolio of blood glucose monitoring systems and the exclusive
global distribution partner for the Eversense® CGM Systems from
Senseonics. These products combine advanced technology with
user-friendly functionality to help people with diabetes manage
their condition and make a positive difference to their lives. As a
trusted partner in the diabetes community, it collaborates closely
with healthcare professionals and other partners to ensure its
products meet the highest standards of accuracy, precision and
reliability, and that it conducts its business compliantly and with
integrity. Ascensia is a member of PHC Group and was established in
2016 through the acquisition of Bayer Diabetes Care by PHC Holdings
Corporation. Ascensia products are sold in more than 100 countries.
Ascensia has around 1,500 employees and operations in 31 countries.
For further information, please visit http://www.ascensia.com
Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Senseonics, including statements regarding
PHC Group’s building of its dedicated CGM business unit, statements
regarding advancing a next-generation, 365-day CGM system to
market, statements regarding growing the awareness, adoption,
growth and potential of Eversense, and other statements containing
the words “believe,” “expect,” “intend,” “may,” “projects,” “will,”
“planned,” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: uncertainties inherent in the ongoing
commercialization of the Eversense product, uncertainties inherent
in PHC Group’s development of a dedicated CGM business,
uncertainties inherent in Ascensia’s performance and other
commercial initiatives, including the ability to hire, retain and
effectively incentivize the dedicated CGM workforce, uncertainties
in the regulatory approval process, uncertainties in insurer,
regulatory and administrative processes and decisions,
uncertainties inherent in the development and registration of new
technology, uncertainties relating to the current economic
environment and such other factors as are set forth in the risk
factors detailed in Senseonics’ Annual Report on Form 10-K for the
year ended December 31, 2022, the Quarterly Report on Form 10-Q for
the quarter ended September 30, 2023 and Senseonics’ other filings
with the SEC under the heading “Risk Factors.” In addition, the
forward-looking statements included in this press release represent
Senseonics’ views as of the date hereof. Senseonics anticipates
that subsequent events and developments will cause Senseonics’
views to change. However, while Senseonics may elect to update
these forward-looking statements at some point in the future,
Senseonics specifically disclaims any obligation to do so except as
required by law. These forward-looking statements should not be
relied upon as representing Senseonics’ views as of any date
subsequent to the date hereof.
1 There is no glucose data generated when the transmitter is
removed. 2 Garg S. et al. Evaluation of Accuracy and Safety of the
Next-Generation Up to 180-Day Long-Term Implantable Eversense
Continuous Glucose Monitoring System: The PROMISE Study. Diabetes
Technology & Therapeutics 2021; 24(2): 1-9.DOI:
10.1089/dia.2021.0182
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240206310306/en/
PHCHD Communications Contact Julia Cottrill
julia.cottrill@phchd.com
Senseonics Investor Contact Philip Taylor Gilmartin Group
415-937-5406 Investors@senseonics.com
Grafico Azioni Senseonics (AMEX:SENS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Senseonics (AMEX:SENS)
Storico
Da Giu 2023 a Giu 2024